Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer — The View From Goodwin <em>(Chambers Associate)</em>

main

07_12 Becoming a Life Sciences Lawyer

Seven partners from Goodwin share their views on what it takes to become a successful life sciences lawyer. 

Becoming a Life Sciences Lawyer — The View From Goodwin (Chambers Associate)

Related Content

District Court Sets Aside FDA’s Interpretation of “Analogous” to a Protein for Purposes of the “Biological Product” Category

A Recap of Resilience: Goodwin’s Life Sciences Practice

Congress Passes Legislation Codifying FDA’s “Active Moiety” Approach to Exclusivity Determinations

Congress Enacts Amendments Affecting The Regulation Of Generic Drugs And Biosimilars

Webinar Recording: Top of Mind Issues for Global Life Sciences Companies in the Era of COVID-19

Qualifying for Immunity Under the U.S. PREP Act During COVID-19

CMS Expands Availability of Advances on Medicare Reimbursement; U.S. CARES Act Increases Medicare Reimbursement Rates

Mobile Medical Apps: Understanding and Defending Against Products Liability Challenges

FDA's AI Launch Raises Training And Accuracy Concerns (Law360 Healthcare Authority)

Blueprint Medicines To Be Acquired By Sanofi For $9.5 Billion Including Contingent Value Rights

Vigil Neuroscience To Be Acquired by Sanofi For $470 Million and Contingent Value Rights

SpringWorks Therapeutics To Be Acquired By Merck KGaA, Darmstadt, Germany For $3.9 Billion

2seventy bio To Be Acquired by Bristol Myers Squibb for $5.00 per Share

AlloVir and Kalaris Therapeutics to Merge

Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones

Benchmark Litigation Names Fourteen Goodwin Partners to 40 & Under Hot List 2024

Life Sciences

FDA Litigation